Floatz logo

Plinabulin

Stage IVb Bladder Cancer

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Stage IVb Bladder Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Pembrolizumab
M.D. Anderson Cancer Center
Phase 1/2B
Relatlimab
M.D. Anderson Cancer Center
Phase 2CCC
Glycosylated Recombinant Human Interleukin-7
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

Plinabulin is also rated in:

small cell lung carcinomaActive
B
Indicative · Phase 2
61 / 100
View asset →
non-small cell lung carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →
cancerDormant
CCC
Indicative · Phase 1/2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →